Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
Vevye Logo Vevye Logo Contact Us

Access for All

Terms and Conditions

  • For patients whose prescriptions are covered by commercial insurance, use of this program may reduce your copayment so that you may pay as little as $0.
  • Eligible commercially insured patients can, for one time only, access VEVYE at no cost while benefits are being verified for one prescription fill, with a maximum of one bottle. Insurance coverage must be approved by the payor for patients to continue receiving medication with no out-of-pocket cost.
  • For patients whose prescriptions are not covered by commercial insurance, use of this program may reduce your cost for prescriptions to as little as $59.
  • This program is not valid for prescriptions paid for in part or full by Medicare, Medicaid, Tricare, DOD, VA, or any state or federally funded program.
  • By enrolling in the VEVYE® Access For All Program, you certify to the following: (1) You will not seek any prescription coverage or reimbursement from your Medicare plan for the cost of the VEVYE prescriptions received through this offer or report any amounts paid in connection with this offer toward your True Out-of-Pocket (TrOOP) costs under your plan; (2) that you will purchase all VEVYE prescriptions covered under this offer during the calendar year by using the VEVYE Access For All Program and will not use your Medicare benefits even if your benefits change; (3) I understand that, upon receiving medication via this program, that my Medicare plan will be notified of my utilization of this program and of the above terms and conditions.
  • This program is subject to overall maximum support amounts.
  • This offer shall be applied only toward the cost of an eligible prescription product and not toward ancillary services or treatment costs.
  • This offer is only good in the United States of America (including the District of Columbia, Puerto Rico, Guam, and the U.S. Virgin Islands).
  • You must present this coupon along with your prescription to participate in this program.
  • This offer is not health insurance.
  • The selling, trading, or counterfeiting of this coupon is prohibited by law. Void if reproduced.
  • This offer is not transferable.
  • When you use this offer, you are certifying that you understand and agree to comply with the program rules, regulations, eligibility requirements, and Terms and Conditions.
  • Harrow reserves the right to rescind, revoke, or amend this offer at any time.

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about VEVYE, please see the Full Prescribing Information.